免疫检查点抑制剂所致皮肤免疫相关不良反应的研究进展

doi:10.35541/cjd.20201221

Abstract

Abstract: 【Abstract】 As a new type of anti-cancer drugs, immune checkpoint inhibitors have been widely used for the treatment of various tumors in recent years, but they have also caused a variety of immune-related adverse reactions, among which cutaneous adverse reactions are the most common. The onset of cutaneous adverse reactions was usually early, and most are mild, but some can also be life-threatening. This review summarizes recent advances in cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors.

Key words: Drug toxicity, CTLA-4 antigen, Programmed cell death 1 receptor, Skin manifestations, Immune checkpoint inhibitors

Zou Meirong, Wang Sheng. Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors[J]. Chinese Journal of Dermatology, 2022, 55(11): 1026-1030.doi:10.35541/cjd.20201221

References ［61］

［1］	Schwartz JC, Zhang X, Fedorov AA, et al. Structural basis for co⁃stimulation by the human CTLA⁃4/B7⁃2 complex［J］. Nature, 2001,410（6828）:604⁃608. doi: 10.1038/35069112.
［2］	Thompson JA. New NCCN guidelines: recognition and management of immunotherapy⁃related toxicity［J］. J Natl Compr Canc Netw, 2018,16（5S）:594⁃596. doi: 10.6004/jnccn.2018.0047.
［3］	Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA⁃4 and PD⁃1 receptors inhibit T⁃cell activation by distinct mechanisms［J］. Mol Cell Biol, 2005,25（21）:9543⁃9553. doi: 10.1128/MCB.25.21. 9543⁃9553.2005.
［4］	Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy⁃related toxicities, version 1.2019［J］. J Natl Compr Canc Netw, 2019,17（3）:255⁃289. doi: 10.6004/jnccn.2019. 0013.
［5］	Tang SQ, Tang LL, Mao YP, et al. The pattern of time to onset and resolution of immune⁃related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients［J］. Cancer Res Treat, 2021,53（2）:339⁃354. doi: 10.4143/crt.2020.790.
［6］	Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade［J］. J Clin Invest, 2018,128（2）:715⁃720. doi: 10.1172/JCI96798.
［7］	Postow MA, Sidlow R, Hellmann MD. Immune⁃related adverse events associated with immune checkpoint blockade［J］. N Engl J Med, 2018,378（2）:158⁃168. doi: 10.1056/NEJMra1703481.
［8］	Lim SY, Lee JH, Gide TN, et al. Circulating cytokines predict immune⁃related toxicity in melanoma patients receiving anti⁃PD⁃1⁃based immunotherapy［J］. Clin Cancer Res, 2019,25（5）:1557⁃1563. doi: 10.1158/1078⁃0432.CCR⁃18⁃2795.
［9］	Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor⁃induced toxic effects with shared cancer and tissue antigens in non⁃small cell lung cancer［J］. JAMA Oncol, 2019,5（7）:1043⁃1047. doi: 10.1001/jamaoncol.2019.0402.
［10］	National Cancer Institute, National Institutes of Health. Common terminology criteria for adverse events （CTCAE） v5.0［EB/OL］. ［2020⁃12⁃25］. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
［11］	Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma［J］. N Engl J Med, 2015,372（26）:2521⁃2532. doi: 10.1056/NEJMoa1503093.
［12］	Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta⁃analysis［J］. J Am Acad Dermatol, 2013,69（3）:e121⁃e128. doi:10.1016/j.jaad.2012.12.963.
［13］	乔瑞, 姜祎群. 常见分子靶向抗肿瘤药物皮肤不良反应及诊治的研究进展［J/OL］.中国皮肤性病学杂志, 2020（2020⁃11⁃16）［2020⁃12⁃25 ］. doi: 10.13735/j.cjdv.1001⁃7089.202006008.
［14］	Donaldson M, Owen JL, Chae YK, et al. Management of persistent pruritus and lichenoid reaction secondary to nivolumab with narrowband ultraviolet B phototherapy［J］. Front Oncol, 2018,8:405. doi: 10.3389/fonc.2018.00405.
［15］	Freeman⁃Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune⁃related adverse events and association with outcomes［J］. Clin Cancer Res, 2016,22（4）:886⁃894. doi: 10.1158/1078⁃0432.CCR⁃15⁃1136.
［16］	Liu RC, Consuegra G, Chou S, et al. Vitiligo⁃like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers［J］. Clin Exp Dermatol, 2019,44（6）:643⁃646. doi: 10.1111/ced.13867.
［17］	Uenami T, Hosono Y, Ishijima M, et al. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report［J］. Lung Cancer, 2017,109:42⁃44. doi: 10.1016/j.lungcan.2017.04. 019.
［18］	Larsabal M, Marti A, Jacquemin C, et al. Vitiligo⁃like lesions occurring in patients receiving anti⁃programmed cell death⁃1 therapies are clinically and biologically distinct from vitiligo［J］. J Am Acad Dermatol, 2017,76（5）:863⁃870. doi: 10.1016/j.jaad. 2016.10.044.
［19］	Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy［J］. J Cutan Pathol, 2017,44（2）:158⁃176. doi: 10.1111/cup.12858.
［20］	斯晓燕, 何春霞, 张丽, 等. 免疫检查点抑制剂相关皮肤不良反应诊治建议［J］. 中国肺癌杂志, 2019,22（10）:639⁃644. doi: 10.3779/j.issn.1009⁃3419.2019.10.06.
［21］	Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti⁃programmed cell death 1 and anti⁃programmed cell death ligand 1 immunotherapy［J］. JAMA Dermatol, 2016,152（10）:1128⁃1136. doi: 10.1001/jamadermatol.2016.2226.
［22］	Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor⁃related dermatologic adverse events［J］. J Am Acad Dermatol, 2020,83（5）:1255⁃1268. doi: 10.1016/j.jaad.2020.03. 132.
［23］	Di Altobrando A, Bruni F, Alessandrini A, et al. Severe de⁃novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma［J］. Dermatol Ther, 2020,33（3）:e13363. doi: 10.1111/dth.13363.
［24］	Bonigen J, Raynaud⁃Donzel C, Hureaux J, et al. Anti⁃PD1⁃induced psoriasis: a study of 21 patients［J］. J Eur Acad Dermatol Venereol, 2017,31（5）:e254⁃e257. doi: 10.1111/jdv. 14011.
［25］	Fattore D, Annunziata MC, Panariello L, et al. Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast［J］. Eur J Cancer, 2019,110:107⁃109. doi: 10. 1016/j.ejca.2019.01.010.
［26］	Johnson D, Patel AB, Uemura MI, et al. IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy［J］. Cancer Immunol Res, 2019,7（6）:860⁃865. doi: 10.1158/2326⁃6066.CIR⁃18⁃0682.
［27］	Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti⁃PD⁃1 and anti⁃PD⁃L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy［J］. J Am Acad Dermatol, 2018,79（6）:1081⁃1088. doi: 10.1016/j.jaad.2018.07. 008.
［28］	Hanley T, Papa S, Saha M. Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma［J］. JRSM Open, 2018,9（10）:2054 270418793029. doi: 10.1177/20542704 18793029.
［29］	Kuwatsuka Y, Iwanaga A, Kuwatsuka S, et al. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab［J］. J Dermatol, 2018,45（1）:e21⁃e22. doi: 10.1111/1346⁃8138.14043.
［30］	Okada H, Kamiya K, Murata S, et al. Case of lichen planus pemphigoides after pembrolizumab therapy for advanced urothelial carcinoma［J］. J Dermatol, 2020,47（9）:e321⁃e322. doi: 10. 1111/1346⁃8138.15461.
［31］	McNally MA, Vangipuram R, Campbell MT, et al. Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma［J］. JAAD Case Rep,2021,10:82⁃84. doi:10.1016/j.jdcr.2021.02.012.
［32］	张悦昕，陈喜雪. 发生于特瑞普利单抗长期治疗后的大疱性类天疱疮二例［J］. 中华皮肤科杂志, 2021, 54（2）: 131⁃135.doi: 10.35541/cjd.20200483.
［33］	Chen WS, Tetzlaff MT, Diwan H, et al. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: a spectrum of immune reactions from paraneoplastic pemphigus⁃like to Grover⁃like lesions［J］. J Cutan Pathol, 2018,45（10）:764⁃773. doi: 10.1111/cup.13312.
［34］	Ridpath AV, Rzepka PV, Shearer SM, et al. Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab⁃induced bullous pemphigoid［J］. Int J Dermatol, 2018,57（11）:1372⁃1374. doi: 10.1111/ijd.13970.
［35］	Damsky W, Jilaveanu L, Turner N, et al. B cell depletion or absence does not impede anti⁃tumor activity of PD⁃1 inhibitors［J］. J Immunother Cancer, 2019,7（1）:153. doi: 10.1186/s40425⁃019⁃0613⁃1.
［36］	Sowerby L, Dewan AK, Granter S, et al. Rituximab treatment of nivolumab⁃induced bullous pemphigoid［J］. JAMA Dermatol, 2017,153（6）:603⁃605. doi: 10.1001/jamadermatol.2017.0091.
［37］	Kremer N, Snast I, Cohen ES, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature［J］. Am J Clin Dermatol, 2019,20（2）:209⁃216. doi: 10.1007/s40257⁃018⁃0401⁃6.
［38］	Wang F, Qin S, Sun X, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial［J］. J Hematol Oncol, 2020,13（1）:47. doi: 10.1186/s13045⁃020⁃00886⁃2.
［39］	秦叔逵, 马军, 李进, 等. 卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识［J］. 临床肿瘤学杂志, 2020,25（09）:840⁃848.
［40］	位变, 王华庆, 柳凤亭, 等. PD⁃1抑制剂卡瑞利珠单抗治疗恶性肿瘤引发反应性皮肤毛细血管增生二例［J］. 中华皮肤科杂志, 2021,54（03）:252⁃253. doi: 10.35541/cjd.20190821.
［41］	Galli G, Proto C, Cossa M, et al. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non⁃small cell lung cancer［J］. Tumori,2019,105（6）:NP57⁃NP62. doi: 10.1177/0300891619872546.
［42］	Kuntz T, Koushk⁃Jalali B, Kreuter A. Sunitinib⁃induced pyoderma gangrenosum⁃like skin ulcer［J］. CMAJ, 2020,192（20）:E552. doi: 10.1503/cmaj.191165.
［43］	Yaşar HA, Akkus E, Heper A, et al. Sweet′s syndrome under ipilimumab therapy and a brief comparison of the cases in literature［J］. J Oncol Pharm Pract, 2020,26（7）:1762⁃1764. doi:10.1177/1078155220906885.
［44］	Salamaliki C, Solomou EE, Liossis SC. Immune checkpoint inhibitor⁃associated scleroderma⁃like syndrome: a report of a pembrolizumab⁃induced "eosinophilic fasciitis⁃like" case and a review of the literature［J］. Rheumatol Ther, 2020,7（4）:1045⁃1052. doi: 10.1007/s40744⁃020⁃00246⁃z.
［45］	Zitouni NB, Arnault JP, Dadban A, et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review［J］. Melanoma Res, 2019,29（2）:212⁃215. doi: 10.1097/CMR.0000000000000536.
［46］	Kosche C, Stout M, Sosman J, et al. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature［J］. Melanoma Res, 2020,30（3）:313⁃316. doi: 10.1097/CMR.0000000000000642.
［47］	Wiggins CJ, Chon SY. Anti⁃CTLA⁃4 therapy⁃associated granuloma annulare in chronic myelomonocytic leukemia［J］. Proc （Bayl Univ Med Cent）, 2020,34（1）:122⁃123. doi: 10.1080/08998280.2020.1818165.
［48］	Page B, Borradori L, Beltraminelli H, et al. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab［J］. J Eur Acad Dermatol Venereol, 2018,32（7）:e256⁃256e257. doi: 10.1111/jdv.14282.
［49］	Matsubara T, Uchi H, Haratake N, et al. Acute generalized exanthematous pustulosis caused by the combination of pembrolizumab plus chemotherapy in a patient with squamous⁃cell carcinoma［J］. Clin Lung Cancer, 2020,21（2）:e54⁃54e56. doi: 10.1016/j.cllc.2019.11.009.
［50］	Maloney NJ, Ravi V, Cheng K, et al. Stevens⁃Johnson syndrome and toxic epidermal necrolysis⁃like reactions to checkpoint inhibitors: a systematic review［J］. Int J Dermatol, 2020,59（6）:e183⁃183e188. doi: 10.1111/ijd.14811.
［51］	Ibraheim H, Perucha E, Powell N. Pathology of immune⁃mediated tissue lesions following treatment with immune checkpoint inhibitors［J］. Rheumatology （Oxford）, 2019,58（Suppl 7）:vii17⁃17vii28. doi: 10.1093/rheumatology/kez465.
［52］	Dasanu CA. Late⁃onset Stevens⁃Johnson syndrome due to nivolumab use for hepatocellular carcinoma［J］. J Oncol Pharm Pract, 2019,25（8）:2052⁃2055. doi: 10.1177/1078155219830166.
［53］	孔英琪, 陈浩. 新型药物的皮肤不良反应［J/OL］. 中国皮肤性病学杂志, 2020（2020⁃11⁃16）［2020⁃12⁃25］. doi: 10.13735/j.cjdv.1001⁃7089.202007104.
［54］	Gopee NH, Gourley AM, Oliphant TJ, et al. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors［J/OL］. Dermatol Online J, 2020,26（8）. doi:10.5070/D3268049884.
［55］	Coleman EL, Olamiju B, Leventhal JS. The life⁃threatening eruptions of immune checkpoint inhibitor therapy［J］. Clin Dermatol, 2020,38（1）:94⁃104. doi: 10.1016/j.clindermatol.2019. 10.015.
［56］	Mirza S, Hill E, Ludlow SP, et al. Checkpoint inhibitor⁃associated drug reaction with eosinophilia and systemic symptom syndrome［J］. Melanoma Res, 2017,27（3）:271⁃273. doi: 10.1097/CMR.0000000000000326.
［57］	Teulings HE, Limpens J, Jansen SN, et al. Vitiligo⁃like depigmentation in patients with stage III⁃IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta⁃analysis［J］. J Clin Oncol, 2015,33（7）:773⁃781. doi: 10.1200/JCO.2014.57.4756.
［58］	Nakamura Y, Teramoto Y, Asami Y, et al. Nivolumab therapy for treatment⁃related vitiligo in a patient with relapsed metastatic melanoma［J］. JAMA Dermatol, 2017,153（9）:942⁃944. doi: 10. 1001/jamadermatol.2017.1679.
［59］	Lopez AT, Geskin L. A case of nivolumab⁃induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein⁃1/programmed death ligand⁃1 inhibitors and recommendations for diagnosis and management［J］. Oncologist, 2018,23（10）:1119⁃1126. doi: 10.1634/theoncologist. 2018⁃0128.
［60］	Min Lee CK, Li S, Tran DC, et al. Characterization of dermatitis after PD⁃1/PD⁃L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case⁃control study［J］. J Am Acad Dermatol, 2018,79（6）:1047⁃1052. doi: 10.1016/j.jaad.2018. 05.035.
［61］	Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of readministration of immune checkpoint inhibitors after immune⁃related adverse events in patients with cancer［J］. JAMA Oncol, 2019,5（9）:1310⁃1317. doi: 10.1001/jamaoncol.2019.1022.

[1]	Gu Ankang, Zhang Yu, Ma Faku, Kong Xiangjun, Zhang Litao. Clinicopathological analysis of 56 cases of swimming pool granuloma [J]. Chinese Journal of Dermatology, 2022, 55(9): 795-798.
[2]	Yang Zhou, Xu Zhe, Wang Zhaoyang, Chen Yunliu, Ma Lin. TP63 gene mutation analysis in a case of ankyloblepharon-ectodermal defects-cleft lip/palate syndrome [J]. Chinese Journal of Dermatology, 2022, 55(8): 696-699.
[3]	Zhang Shimin, Hu Yunyun, Zhao Xiaoqing, Du Lianjun, Cao Hua, Zheng Jie. Application of imaging techniques in diagnosis and severity assessment of dermatomyositis [J]. Chinese Journal of Dermatology, 2022, 55(7): 637-640.
[4]	Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 55(7): 603-609.
[5]	Wang Yuan, Li Zhiliang, Li Suo, Jing Ke, Sun Chao, Liang Guirong, Zhang Hanmei, Feng Suying. Clinical and immunoserological features of 7 cases of anti-p200 pemphigoid [J]. Chinese Journal of Dermatology, 2022, 55(7): 557-561.
[6]	Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565.
[7]	Shih Yanting, Li Hao, Zheng Jie, Cao Hua. Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies [J]. Chinese Journal of Dermatology, 2022, 55(7): 633-636.
[8]	Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493.
[9]	Shen Chen, Chen Junjun, Yang Ji, Hu Dongyan, Xin Chongmei, Li Ming. Clinical features and classification of 180 patients with morphea [J]. Chinese Journal of Dermatology, 2022, 55(4): 308-315.
[10]	Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298.
[11]	Wang Zhaoyang, Chen Anwei, Xiang Xin, Luo Xiaoyan, Xu Zigang, Wang Hua, Ma Lin. An investigation into the current situation of pediatric psoriasis based on the information systems from two children′s hospitals [J]. Chinese Journal of Dermatology, 2022, 55(3): 246-250.
[12]	Li Hao, Wang Li, Han Xianwei, Sun Tong, Su Fang, Sun Xiaodong, Han Ying, Yang Guoling, Liu Xiaoming, Wang Kaibo. Analysis of clinical characteristics of bullous pemphigoid developing after the treatment with dipeptidyl peptidase-Ⅳ inhibitors in 32 patients with diabetes mellitus [J]. Chinese Journal of Dermatology, 2022, 55(3): 213-218.
[13]	Han Xiaofeng, Sun Juan, Qiu Lei, Wei Li, Ma Lin. Analysis of clinical and pathological features of 29 cases of perforating pilomatricoma [J]. Chinese Journal of Dermatology, 2022, 55(3): 196-199.
[14]	Wang Yue, Yan Yulin. Analysis of adverse drug reactions and reasons for drug discontinuation during acitretin therapy in 171 patients with psoriasis vulgaris [J]. Chinese Journal of Dermatology, 2022, 55(3): 242-245.
[15]	Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275.

Cutaneous immune-related adverse reactions induced by immune checkpoint inhibitors

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［61］

Related Articles 15

Metrics

Comments

Recommended 10